Coredio Company Profile

Background

Overview

Coredio is a healthcare technology company specializing in non-invasive cardiac diagnostics. Founded in 2023 and headquartered in Mountain View, California, Coredio leverages artificial intelligence (AI), digital twin modeling, and wearable technology to provide real-time monitoring of cardiac metrics. This innovative approach aims to enhance the detection and management of cardiovascular diseases, particularly heart failure, by offering continuous, non-invasive insights into patients' cardiac health.

Mission and Vision

Coredio's mission is to revolutionize cardiovascular care by delivering accessible, accurate, and continuous cardiac monitoring solutions. The company's vision is to empower healthcare providers and patients with advanced tools that facilitate proactive management of heart health, thereby improving patient outcomes and reducing hospital readmissions.

Industry Significance

In the context of the growing prevalence of cardiovascular diseases worldwide, Coredio's innovative approach addresses a critical need for non-invasive, continuous monitoring solutions. By integrating AI and wearable technologies, Coredio is positioned to make a significant impact on the healthcare industry, offering scalable solutions that can be implemented across various healthcare settings.

Key Strategic Focus

Core Objectives

Non-Invasive Monitoring: Develop and deploy non-invasive cardiac monitoring solutions that provide real-time data on cardiac output and central blood pressure.

AI Integration: Utilize artificial intelligence to analyze cardiac data, enabling personalized treatment plans and early detection of potential health issues.

Wearable Technology: Leverage existing wearable devices to collect continuous cardiac data, enhancing patient comfort and compliance.

Areas of Specialization

Cardiac Diagnostics: Focus on providing accurate and continuous monitoring of cardiac metrics without the need for invasive procedures.

Digital Twin Modeling: Employ digital twin technology to create personalized simulations of patients' cardiac systems, facilitating precise monitoring and management.

Key Technologies Utilized

Artificial Intelligence (AI): For data analysis and predictive modeling.

Digital Twin Technology: To create personalized simulations of patients' cardiac systems.

Wearable Devices: To collect continuous cardiac data from patients.

Primary Markets Targeted

Healthcare Providers: Hospitals and clinics seeking advanced tools for cardiac care.

Patients with Heart Failure: Individuals requiring continuous monitoring of their cardiac health.

Financials and Funding

Funding History

Coredio has completed one funding round:

Seed Round: Announced in May 2024, with participation from Plug and Play. The exact amount raised remains undisclosed.

Investors

Plug and Play: A global innovation platform that invested in Coredio's seed round.

Utilization of Capital

The funds raised are intended to support the development and clinical validation of Coredio's Cardiac Performance Simulation (CPS™) platform, as well as to advance regulatory processes, including seeking FDA breakthrough designation.

Pipeline Development

Key Pipeline Candidates

Cardiac Performance Simulation (CPS™) Platform: A non-invasive software platform that utilizes digital twin technology and AI to monitor cardiac metrics equivalent to those obtained through catheterization procedures.

Stages of Development

Clinical Validation: Coredio is in the process of validating the CPS™ platform through preliminary testing with heart failure patients undergoing cardiac catheterization.

Target Conditions

Heart Failure: The primary focus is on managing and monitoring heart failure patients.

Anticipated Milestones

FDA Breakthrough Designation: Coredio is seeking FDA breakthrough designation to expedite the regulatory process for the CPS™ platform.

Technological Platform and Innovation

Proprietary Technologies

Cardiac Performance Simulation (CPS™): A proprietary software platform that creates personalized digital twin models of patients' cardiac systems, enabling continuous, non-invasive monitoring.

Significant Scientific Methods

Digital Twin Modeling: Utilized to simulate individual patients' cardiac systems for precise monitoring.

Artificial Intelligence (AI): Employed for analyzing cardiac data and generating predictive insights.

AI-Driven Capabilities

Predictive Analytics: AI algorithms analyze cardiac data to predict potential health issues, facilitating early intervention.

Personalized Treatment Plans: AI assists in developing tailored treatment strategies based on individual patient data.

Leadership Team

Yashar Seyed Vahedein – Co-Founder and CEO

Professional Background: Holds a Ph.D. in Engineering from the Rochester Institute of Technology. Previously served as a Staff Data Scientist at BD.

Role at Coredio: Oversees the company's strategic direction and operations.

Mehdi Mortazawy – Co-Founder and CTO

Professional Background: Graduated in Aerospace Engineering with a focus on Computational Physics from Embry-Riddle Aeronautical University. Former Senior Fluid Dynamics Engineer at Dassault Systèmes.

Role at Coredio: Leads the technological development and innovation efforts.

Competitor Profile

Market Insights and Dynamics

The healthcare technology sector, particularly in non-invasive cardiac diagnostics, is experiencing significant growth due to the increasing prevalence of cardiovascular diseases and the demand for continuous monitoring solutions. Advancements in AI and wearable technologies are driving innovation in this space.

Competitor Analysis

Tempus: Focuses on precision medicine and AI-driven diagnostics, offering solutions in oncology and other therapeutic areas.

GE Healthcare: Provides a wide range of medical imaging and monitoring equipment, including solutions for cardiac care.

BD (Becton, Dickinson and Company): A global medical technology company offering a variety of diagnostic and monitoring devices.

Strategic Collaborations and Partnerships

Coredio has engaged in collaborations to advance its technology:

Roux Institute: Provided mentorship and regulatory guidance to support Coredio's pursuit of FDA breakthrough designation.

Operational Insights

Coredio's focus on non-invasive, AI-driven cardiac monitoring differentiates it from competitors by offering continuous, personalized insights without the need for invasive procedures. This approach aligns with the growing trend towards patient-centric, technology-enabled healthcare solutions.

Strategic Opportunities and Future Directions

Strategic Roadmap

Regulatory Advancement: Pursue FDA breakthrough designation to expedite the approval process for the CPS™ platform.

Clinical Expansion: Expand clinical trials to validate the platform's effectiveness across diverse patient populations.

Market Penetration: Increase adoption among healthcare providers and patients through strategic partnerships and targeted marketing efforts.

Future Business Directions

Product Diversification: Develop additional features and modules to address a broader range of cardiovascular conditions.

Global Expansion: Explore international markets to extend the reach of Coredio's solutions.

Opportunities for Expansion

Coredio's innovative approach positions it to capitalize on the growing demand for non-invasive, continuous cardiac monitoring solutions, offering significant opportunities for expansion in both domestic and international markets.